Nurix Therapeutics, Inc. (NRIX) Stock Price & How to Invest

Last updated November 2026

Short answer

You can invest in Nurix Therapeutics (NRIX) by buying shares or fractional shares at any major broker, or as one holding in a thematic biotech basket. Nurix is a clinical-stage drug developer built around targeted protein degradation, a technology that tags disease-causing proteins for the cell to destroy, and its value hinges almost entirely on the clinical progress of its lead BTK degrader bexobrutideg rather than on current profits. As of November 20, 2026 the shares closed at $13.05, down about 28% year to date and 15% over one year, for a market value of roughly $1.4 billion, after a record 38% one-day fall on November 4 when Sanofi ended a STAT6 program licensed from Nurix.

NRIX stock price

As of 2026-11-20, Nurix Therapeutics, Inc. (NRIX) last closed at $12.85, down 23.3% over the past year. Over the past 52 weeks it has traded between $12.85 and $27.79.

NRIX last close
$12.85
1 day
-5.51%
1 month
-50.61%
1 year
-23.33%
52-week range
$12.85 to $27.79
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Nurix Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.

NRIX key stats

At $12.85 on November 20, 2026, Nurix Therapeutics, Inc. (NRIX) has a market cap of $1.4B and a P/E of 5.3 on trailing earnings. It next reports earnings around January 28, 2027 (estimated).

Market cap
$1.4B
P/E (trailing)
5.3
EPS (trailing 12 months)
$2.43
Price to book
1.4
Beta
1.78
Next earnings
around January 28, 2027 (estimated)

Market cap, P/E and yield are measured at the $12.85 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Nurix Therapeutics, Inc. (NRIX)?

The last two weeks for Nurix Therapeutics, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • NRIX closed at $12.85 on November 20, 2026, down 17.0% over the past five trading days (from $15.48).
  • Nurix Therapeutics, Inc. next reports quarterly results around January 28, 2027 (estimated).

Nurix Therapeutics, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Nurix Therapeutics, Inc. (NRIX) do?

Nurix Therapeutics is a clinical-stage biopharmaceutical company that designs targeted protein degradation medicines, small molecules that harness the body's own protein-disposal machinery to eliminate disease-driving proteins rather than merely blocking them. Its lead program, bexobrutideg (NX-5948), is an oral, brain-penetrant degrader of BTK being studied in chronic lymphocytic leukemia and other blood cancers, with a registrational Phase 2 DAYBreak CLL-201 study supporting a potential accelerated approval and a Phase 3 DAYBreak CLL-306 study, comparing it with pirtobrutinib in about 620 patients, that enrolled its first patient by October 2026. Beyond bexobrutideg, Nurix has wholly owned programs including zelebrudomide (NX-2127) and the CBL-B inhibitor NX-1607, plus partnered discovery work with Gilead Sciences, Sanofi, and Pfizer where it retains options to co-develop and share profits.

The investment picture is that of a platform biotech: Nurix generates only modest collaboration revenue, spends heavily on research, and posts large net losses funded by a sizable cash reserve. In June 2026 it announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg across hematology, immunology, and neurology, a multi-billion-dollar deal (in potential milestones) that validates the asset and adds non-dilutive funding. The deal carried a $700 million upfront payment, and in its fiscal third quarter (ended August 31, 2026) Nurix booked about $673.1 million of revenue, roughly $653.2 million of it Roche license revenue, and net income of about $549.8 million ($4.73 per diluted share, against a consensus near $5.02). Cash and marketable securities rose to about $1.1 billion, which the company says funds operations into the second half of 2029. That profit is a one-time effect of the upfront payment; analysts expect a loss of about $1.28 per share in fiscal 2027.

The partnered pipeline then took a hit. On November 4, 2026 Sanofi said it was ending SAR448272, an oral drug licensed from Nurix under their 2019 collaboration and in an early first-in-human trial for type 2 inflammatory conditions such as atopic dermatitis and asthma. Nurix had been eligible for about $455 million of additional milestones on that asset plus royalties, having already received about $139 million from Sanofi overall. NRIX fell about 38% that day, its worst day ever, and Wells Fargo cut its price target to $20 from $25. Nurix said the news does not change its cash runway guidance, and it remains eligible for milestones on other Sanofi programs. In November it also named Arati V. Rao, M.D., as chief medical officer and said it would present new and updated bexobrutideg CLL data at the 68th ASH Annual Meeting. The shares closed at $13.05 on November 20, 2026, down about 49% over the past month and at the bottom of a $13.03 to $28.23 52-week range. Returns depend on whether the registrational trials read out positively, whether bexobrutideg reaches the market, and how the remaining partnership milestones convert into cash, all of which remain uncertain.

What's driving Nurix Therapeutics, Inc. (NRIX)?

1. Bexobrutideg registrational path.

The lead value driver is bexobrutideg, an oral BTK degrader positioned as potentially best-in-class in relapsed or refractory CLL. The registrational Phase 2 DAYBreak CLL-201 study, enrolling patients previously treated with covalent BTK, BCL2, and non-covalent BTK inhibitors, is intended to support an accelerated approval. The confirmatory Phase 3 DAYBreak CLL-306, a randomized head-to-head study against pirtobrutinib in about 620 patients with response rate and progression-free survival as dual primary endpoints, has enrolled its first patient, and a Phase 1b/2 study combining bexobrutideg with venetoclax began recruiting in October 2026. Positive, durable response data would be the single largest catalyst for the stock. New and updated data from the ongoing Phase 1a/1b trial in relapsed or refractory CLL/SLL are due at the 68th ASH Annual Meeting.

2. Roche collaboration.

In June 2026 Nurix announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology, and neurology. The deal brought a $700 million upfront payment plus milestones and shared development costs, and its effect was visible immediately: fiscal third-quarter revenue reached about $673 million and R&D expense fell to about $79.3 million as Roche's cost sharing offset spending. It validates the asset and extends Nurix's runway with non-dilutive capital while keeping the company exposed to commercial upside.

3. Partnered pipeline and platform.

Nurix earns collaboration revenue and future milestones from partnerships with Gilead Sciences (an IRAK4 degrader), Sanofi, and Pfizer. These deals help fund the platform and provide multiple shots on goal beyond the wholly owned CLL programs, though the largest partnered payments are contingent on downstream clinical and regulatory progress. In October 2026 Gilead extended the research term on one oncology program by two years for a $10 million fee, and Sanofi paid a $10 million development milestone in the August quarter. The contingency became concrete on November 4, 2026, when Sanofi ended SAR448272, its STAT6 program licensed from Nurix, removing about $455 million of potential milestones; Nurix remains eligible for milestones and royalties on other Sanofi programs.

4. Immunology and pipeline expansion.

Beyond oncology, Nurix is pursuing autoimmune and inflammatory uses, including an IND target for a tablet formulation of bexobrutideg in immunology, plus additional degraders like NX-1607. Broadening from cancer into larger autoimmune markets is how the platform could scale, but these programs are earlier and years from potential revenue.

What are the risks to Nurix Therapeutics, Inc. (NRIX)?

As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so outside the one-time Roche quarter it posts substantial net losses (analysts expect about -$1.28 per share in fiscal 2027) and depends on its cash balance and partner payments to keep funding trials. The roughly $1.1 billion cash position eases near-term funding pressure. The value is concentrated in bexobrutideg, making the stock highly sensitive to a single set of trial readouts: disappointing efficacy or safety data, a regulatory setback, or a slower-than-expected registrational path could sharply reduce the valuation. Partner risk is real, as November 2026 showed: Sanofi's decision to end SAR448272 cut about $455 million of potential milestones and sent the shares down about 38% in a day, and Wells Fargo said it had attributed about $400 million of value to the program. The company competes in a crowded targeted-protein-degradation field against Arvinas, Kymera, C4 Therapeutics, and large pharma, and against established BTK inhibitors already on the market. Future equity raises could dilute shareholders, and remaining milestone payments from Roche, Gilead, Sanofi, and Pfizer are contingent and may never fully materialize. This is a high-risk, high-volatility name unsuitable for investors who need current income or capital preservation.

What is the Nurix Therapeutics, Inc. (NRIX) forecast?

14 analysts publish price targets on NRIX, averaging $33.50 as of November 2026, or +160.7% against the $12.85 share price on November 20, 2026. The published targets run from $20.00 to $41.00, a moderate spread, and the ratings split 13 buy, 1 hold, 0 sell. Over the last six months there have been 7 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full NRIX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is NRIX a buy or a sell?

We give no verdict on Nurix Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Bexobrutideg registrational path. The lead value driver is bexobrutideg, an oral BTK degrader positioned as potentially best-in-class in relapsed or refractory CLL. The most optimistic published target, $41.00, assumes this works close to its best case.

The case against. As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so outside the one-time Roche quarter it posts substantial net losses (analysts expect about -$1.28 per share in fiscal 2027) and depends on its cash balance and partner payments to keep funding trials. The most pessimistic target, $20.00, is roughly what NRIX is worth if this bites instead.

Read the full bull and bear case on NRIX, including what would have to change to break either one. Walnut is not an investment adviser.

Has Nurix Therapeutics, Inc. (NRIX) split its stock?

No. Nurix Therapeutics, Inc. (NRIX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Nurix Therapeutics, Inc. (NRIX) valued?

Market cap, P/E and dividend yield at today's price are in the NRIX key stats above. The business figures below come from Nurix Therapeutics, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (Q3 FY2026, quarter ended Aug 31 2026): ~$673.1 million (~$653.2 million Roche license revenue)
  • Net income (Q3 FY2026): ~$549.8 million (~$4.73 per share vs ~$5.02 consensus)
  • Revenue (TTM): ~$702 million
  • Net income (TTM): ~$295 million
  • Cash & marketable securities (Aug 31 2026): ~$1.1 billion (runway into 2H 2029)
  • Fiscal 2027 EPS estimate: ~-$1.28 (return to losses)

As of November 2026: Nurix's trailing P/E of about 5x is an artifact of one quarter: the Roche upfront payment produced roughly $550 million of net income in the August 2026 quarter, and analysts expect losses to resume in fiscal 2027. The market still values it on pipeline potential, partnership economics, and cash runway. With about $1.1 billion of cash against a market value near $1.4 billion after the Sanofi-driven selloff, investors are now assigning only about $0.3 billion to bexobrutideg and the rest of the pipeline, which is funded into the second half of 2029; dilution risk has eased while clinical risk remains. The 14 analysts Yahoo Finance tracks carry a mean target near $33.50, though several were set before the Sanofi news.

Who competes with Nurix Therapeutics, Inc. (NRIX)?

Targeted protein degradation peers

Arvinas, Kymera Therapeutics, and C4 Therapeutics are the closest pure-play degrader companies, all racing to advance PROTAC and molecular-glue degraders in oncology and immunology. Arvinas (with Pfizer) reached the first FDA-approved PROTAC in breast cancer, while Kymera leads in immunology degraders like STAT6 and IRAK4, making them direct platform and pipeline rivals to Nurix.

Established BTK-targeting therapies

Bexobrutideg competes against approved BTK inhibitors used in CLL and other B-cell cancers, including AbbVie and Johnson & Johnson's ibrutinib, AstraZeneca's acalabrutinib, and BeiGene's zanubrutinib. Nurix's thesis is that degrading BTK, rather than inhibiting it, can overcome resistance mutations, but these entrenched drugs set the efficacy and safety bar.

Large-pharma partners and platform owners

Big pharmaceutical companies such as Roche, Gilead, Sanofi, Pfizer, and Bristol Myers Squibb both partner with and compete against degrader specialists. They provide Nurix with funding and validation through collaborations, yet also build internal degradation programs, so they are simultaneously customers and long-run competitors.

What stocks are similar to Nurix Therapeutics, Inc. (NRIX)?

Other names that sit close to NRIX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Nurix Therapeutics, Inc. (NRIX)

There are three common ways to get NRIX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so NRIX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NRIX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Nurix Therapeutics, Inc. (NRIX)

Nurix is a clinical-stage biotech whose stock trades on trial data, partnership economics, and cash runway rather than earnings. The Roche deal produced a one-time profitable quarter and lifted cash to about $1.1 billion (runway into the second half of 2029), and after Sanofi dropped a partnered program in November the market value of about $1.4 billion sits only modestly above that cash. Analysts expect losses to resume in fiscal 2027, so it still carries binary clinical risk alongside the upside of a validated protein-degradation platform.

More on Nurix Therapeutics, Inc. (NRIX)

Whether NRIX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NRIX a buy or a sell?, and where the stock could go from here in the NRIX stock forecast.

For income investors, whether NRIX pays a dividend and how the payout looks is covered in does NRIX pay a dividend? And to weigh NRIX against a peer, read the full side-by-side comparisons: NRIX vs PFE and NRIX vs ABBV.

Wondering how NRIX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Nurix Therapeutics, Inc.

Ask Walnut's AI anything about NRIX and see how it fits what you own.

FAQ

What does Nurix Therapeutics do?

+

Nurix is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines, drugs that recruit the cell's natural disposal system to destroy disease-causing proteins. Its focus spans cancer plus autoimmune and inflammatory diseases, led by the oral BTK degrader bexobrutideg.

Is NRIX profitable?

+

Not on a recurring basis. In its fiscal third quarter (ended August 31, 2026) Nurix reported about $673.1 million of revenue and net income of roughly $549.8 million, but that came almost entirely from license revenue under the new Roche collaboration. In the prior quarters it lost about $87-90 million each, and analysts expect a loss of about $1.28 per share in fiscal 2027.

What is bexobrutideg?

+

Bexobrutideg (NX-5948) is Nurix's lead drug candidate, an investigational oral, brain-penetrant degrader of BTK. It is being studied in the registrational Phase 2 DAYBreak CLL-201 trial in relapsed or refractory chronic lymphocytic leukemia, and a Phase 3 confirmatory study against pirtobrutinib (DAYBreak CLL-306) enrolled its first patient by October 2026.

Why did Nurix partner with Roche?

+

In June 2026 Nurix announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg across hematology, immunology, and neurology. The deal brought a $700 million upfront payment plus milestone payments plus shared development costs, validating the asset and providing non-dilutive funding while Nurix keeps commercial upside.

How much cash does Nurix have?

+

Nurix reported about $1.1 billion in cash, cash equivalents, and marketable securities as of August 31, 2026, up from about $540.7 million at February 28, 2026, after receiving the Roche upfront payment. The company says that reserve funds operations into the second half of 2029. After Sanofi ended SAR448272 in November 2026, Nurix said the news does not change that runway guidance.

Who are Nurix's competitors?

+

In targeted protein degradation, Nurix competes with Arvinas, Kymera Therapeutics, and C4 Therapeutics, plus large players like Bristol Myers Squibb. Its BTK degrader also competes with approved BTK inhibitors from AbbVie, Johnson & Johnson, AstraZeneca, and BeiGene.

What are the main risks of owning NRIX?

+

The biggest risks are clinical: value is concentrated in bexobrutideg, so a trial or regulatory setback could sharply cut the valuation. Partner decisions matter too, as Sanofi's November 2026 exit from SAR448272 showed. Other risks include large ongoing losses, potential dilution from equity raises, contingent partner milestones, and intense competition. It is a high-volatility, speculative biotech.

How did Nurix do in its latest quarter?

+

For the fiscal third quarter ended August 31, 2026 (reported October 12), Nurix posted revenue of about $673.1 million and net income of about $549.8 million, or $4.73 per share against a consensus near $5.02. Nearly all of it was Roche license revenue. R&D expense fell to about $79.3 million on Roche cost sharing, and shares slipped about 2% after the report.

Why did Nurix stock fall in November 2026?

+

On November 4, 2026 Sanofi said it was ending development of SAR448272, an oral drug for type 2 inflammatory conditions that it licensed from Nurix in 2019. Nurix had been eligible for about $455 million of additional milestones on it plus royalties. NRIX fell about 38% that day, its worst day ever. Nurix said its cash runway into the second half of 2029 is unchanged.

How has NRIX stock performed in 2026?

+

As of the November 20, 2026 close of $13.05, Nurix shares were down about 28% year to date and about 15% over one year, at the bottom of a 52-week range of about $13.03 to $28.23. They were up about 38% for the year in mid-October before falling about 49% over the following month, including a 38% drop on November 4 after Sanofi ended a licensed program; Wells Fargo cut its target to $20 from $25. Walnut is not an investment adviser, and this describes past prices only.

How can I invest in NRIX?

+

Nurix trades on the Nasdaq under the ticker NRIX. You can buy whole or fractional shares through any major brokerage, or gain indirect exposure through biotech or protein-degradation-focused ETFs that hold it. Walnut is not an investment adviser, so size any position to your own risk tolerance.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Nurix Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.